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Abstract: The current treatments for lymphatic filariasis and onchocerciasis do not effectively kill
the adult parasitic nematodes, allowing these chronic and debilitating diseases to persist in millions
of people. Thus, the discovery of new drugs with macrofilaricidal potential to treat these filarial
diseases is critical. To facilitate this need, we first investigated the effects of three aspartyl protease
inhibitors (APIs) that are FDA-approved as HIV antiretroviral drugs on the adult filarial nematode,
Brugia malayi and the endosymbiotic bacteria, Wolbachia. From the three hits, nelfinavir had the
best potency with an IC50 value of 7.78 µM, followed by ritonavir and lopinavir with IC50 values
of 14.3 µM and 16.9 µM, respectively. The three APIs have a direct effect on killing adult B. malayi
after 6 days of exposure in vitro and did not affect the Wolbachia titers. Sequence conservation and
stage-specific gene expression analysis identified Bm8660 as the most likely primary aspartic protease
target for these drug(s). Immunolocalization using antibodies raised against the Bm8660 ortholog of
Onchocerca volvulus showed it is strongly expressed in female B. malayi, especially in metabolically
active tissues such as lateral and dorsal/ventral chords, hypodermis, and uterus tissue. Global
transcriptional response analysis using adult female B. pahangi treated with APIs identified four
additional aspartic proteases differentially regulated by the three effective drugs, as well as significant
enrichment of various pathways including ubiquitin mediated proteolysis, protein kinases, and
MAPK/AMPK/FoxO signaling. In vitro testing against the adult gastro-intestinal nematode Trichuris
muris suggested broad-spectrum potential for these APIs. This study suggests that APIs may serve as
new leads to be further explored for drug discovery to treat parasitic nematode infections.
Keywords: Neglected tropical diseases (NTDs); filarial nematodes; macrofilaricidal; anti-filarial
drugs; gastro-intestinal nematodes; Trichuris
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Neglected tropical diseases (NTDs) impact more than one billion people worldwide,
primarily in resource-limited countries in tropical and sub-tropical regions [1]. Lymphatic
filariasis (LF) is an NTD that is targeted for elimination; it is caused by the filarial nematodes
Brugia malayi, Brugia timori, and Wuchereria bancrofti [2]. Chronic infection results in swollen
legs, arms, and genitalia, which can lead to severe disability, social stigma, and decreased
productivity [2]. Mass drug administration (MDA) for LF is administered to an entire
at-risk population using a combination of two [3], or more recently, all three (“triple drug
treatment”) of the mostly embryostatic or microfilaricidal drugs: albendazole, diethylcarbamazine citrate (DEC), and ivermectin [2,4,5]. These anthelmintics kill microfilariae over
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the lifetime of the adult worms (6–8 years for Wuchereria and Brugia spp. [6,7]). In 2018, an
estimated 51 million people were infected with LF, which was about half the number of
infected individuals in 2000 [8]. Although the global disease burden has declined due to
MDA, LF elimination is still challenging in many areas and infection continues to lead to
devastating and disabling illnesses in many individuals [9].
Elimination of LF has been challenging, due to the complex life cycle of the filarial
worms and the inability of current treatments to clear the adult life stages of the filarial
worms that cause the disease symptoms [8,10]. The World Health Organization recommends MDA for LF once per year for at least 5 years to cover the reproductive life span of
the adult worms. Since compliance with MDA is suboptimal in many areas, many more
rounds of MDA are often necessary to interrupt the transmission of microfilariae [4,5]. The
presence of other co-endemic NTDs, specifically loiasis and onchocerciasis, determines
which combination of drugs can be used [4]. Additionally, since the Brugia species rely on
the endosymbiotic Wolbachia for development, fertility, and survival, Wolbachia is considered an excellent target for drug therapies [11,12]. Doxycycline is the primary treatment
used to target Wolbachia, and although it is relatively inexpensive and readily available,
patients must take it daily for 4 to 6 weeks, which prevents it from being easily administered
through MDA [5]. Given that the recommended treatments do not effectively kill the adult
filarial worms and there are complications based on the co-endemicity of other NTDs, the
discovery of new and more efficacious drugs is critical.
One approach to identify new candidates to treat filarial diseases involves the use
of repurposed drugs to screen for potential candidates [13]. The advantages of screening
repurposed drugs are that many are already FDA-approved and considerable information
is readily available on their safety and efficacy in humans, thus circumventing costly
preclinical assays and making them more cost-effective [14–16]. Commercially available
aspartyl protease inhibitors (APIs) have been shown to have macrofilaricidal effects in
in vitro studies with adult B. pahangi, adult O. ochengi and L4 stages of O. volvulus [13],
including APIs that are FDA-approved as antiretroviral drugs for human immunodeficiency
virus (HIV) and acquired immunodeficiency syndrome (AIDS) such as lopinavir, nelfinavir,
and ritonavir [17]. The target of the HIV antiretroviral drugs is the HIV-1 aspartyl protease,
which is essential for the HIV to mature [17]. Aspartyl proteases belong to a class of
proteolytic enzymes and are important in maintaining cellular functions, including cell
fertilization, cell-to-cell interactions, and DNA replication and transcription [18]. Proteases
dominate the list of targets for human diseases [19]; thus, conservation and diversification
across the protease superfamily among parasitic nematodes has been explored [20]. For
example, the expansion of protease families has been reported to occur due to differences
in host tissue penetration (skin vs. oral) or feeding (digestion of blood vs. cellular content),
but some level of conservation has also been detected [20]. Because polyparasitism (LF and
onchocerciasis, or filarial and gastro-intestinal nematodes) is still widespread across rural
communities in endemic countries [21], exploring the broad-spectrum potential of APIs is
of great interest.
The purpose of this study is to expand the assessment of the efficacy of several APIs
on the Brugia filarial nematode, to determine their effect on the Wolbachia endosymbiont,
to immunolocalize the putative aspartic protease target in the adult Brugia worms, and to
better understand worm responses to API treatment at the transcriptional level. The new
findings confirmed that APIs warrant further study as new candidate leads for the filarial
and gastro-intestinal nematode drug discovery program.
2. Materials and Methods
2.1. In Vitro Worm Motility Assays
2.1.1. Adult Female B. malayi
Adult female B. malayi were obtained from the Filariasis Research Reagent Resource
Center (FR3) at the University of Georgia, Athens. Each well in a 24-well plate contained
one adult female B. malayi and media (RPMI-1640 with 25 mM HEPES, 2.0 g/L NaHCO3 ,
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5% heat inactivated FBS, and 1X antibiotic/antimycotic solution) [13,22,23]. 10 mg of
lopinavir (catalog #: S1380), nelfinavir (catalog #: S4282), and ritonavir (catalog #: S1185)
were purchased from Selleckchem. A 10 mM stock solution was prepared with dimethyl
sulfoxide (DMSO, Sigma-Aldrich D2650, St. Louis, MO, USA) and was diluted in culture
media to achieve 1% DMSO in the final mixture. The negative control was 1% DMSO. The
motility of the worms was measured using the Worminator instrument on days 0, 1, 2, 3,
and 6 of exposure [23]. Each day, the plates of worms were recorded for 60 s using the
Worminator, and the WormAssay application determined the number of pixels displaced
per second for individual worms using the Lucas-Kanade optical flow algorithm (velocity,
1 organism per well) and calculated the mean movement units (MMUs) for each worm [23].
The percentage of inhibition of motility was calculated by dividing the MMUs of treated
worms by the average MMUs of the control worms, then subtracting that value from 1 [23].
The values were floored to zero and multiplied by 100% [23].
Seven APIs were tested at single concentrations to determine the best hits (>75%
inhibition of worm motility). Lopinavir and nelfinavir were tested at 30 µM and 10 µM.
Amprenavir, atazanavir, and ritonavir were tested at 50 µM and 30 µM. Darunavir and
pepstatin A were tested at 50 µM. The negative control was 1% DMSO. The worms were
incubated at 37 ◦ C with 5% CO2 for the duration of the assay [13].
Based on the worm assays that tested single concentrations over 6 days, the best hits
were selected. IC50 assays were conducted for lopinavir, nelfinavir, and ritonavir using
six-point dilutions (100 µM to 0.3 µM, 30 µM to 0.1 µM, and 300 µM to 1 µM, respectively).
The negative control for this assay was 1% DMSO. The worms were incubated at 37 ◦ C
with 5% CO2 throughout the assay. Prism 6.0 was used to calculate the IC50 values with a
non-linear regression curve [22,23].
2.1.2. Adult T. muris
In vitro screening was performed as previously described [24], and adult T. muris were
provided by Dr. Joseph Urban (USDA). On the day of arrival (day 0), adult worms were
washed as described above and 2 worms were plated into each of 24-well plates containing
500 µL culture media. For each API treatment, 4 biological replicates were prepared. The
APIs were tested at 50 µM and 100 µM, and control worms were treated with 1% DMSO and
maintained at 37 ◦ C with 5% CO2 . The motility of the worms was observed daily on days 0
to 3 using the Worminator approach described above and the MMUs were estimated using
the WormAssay software with the consensus voting luminance difference algorithm [23].
Prism 6.0 was used to calculate the IC50 values with a non-linear regression curve [22,23].
2.2. Determining Wolbachia Titers
To determine Wolbachia titers, adult female B. malayi were collected on day 1 when the
worms were moribund after exposure to 100 µM lopinavir, 30 µM nelfinavir, and 30 µM
ritonavir, respectively. Genomic DNA (gDNA) was extracted from B. malayi using the
QIAGEN DNeasy Blood & Tissue Kit and the purity of the gDNA was quantified based on
the 260/280 ratio (>1.8) using the NanoDrop™ Onec from Thermo Fisher Scientific.
The Wolbachia titers were determined by measuring the abundance of the single
copy gene Wolbachia surface protein (wsp) using a quantitative real-time polymerase
chain reaction (qPCR) [25,26]. The glutathione-S-transferase (gst) gene, a single-copy
gene in the Brugia species, was used to normalize the wsp/gst ratio. The qPCR forward and reverse primers for wsp were 50 -CCCTGCAAAGGCACAA GTTATTG-30 and 50 CGAGCTCCAGCAAAGAGTTTAATTT-30 , respectively [25,26]. The qPCR forward and reverse primers for gst were 50 -GAGACACCTTGCTCGCAAAC-30 and 50 -ATCACGGACGCCTTCACAG-30 , respectively [25,26].
The qPCR was performed using the Bio-Rad CFX Connect thermocycler with the
following conditions for wsp: 95 ◦ C for 15 min, 40 cycles of denaturation at 94 ◦ C for 10 s,
annealing at 57 ◦ C for 20 s, and elongation at 72 ◦ C for 15 s [25,26]. The melting curve
analysis involved heating to 95 ◦ C for 1 min, annealing at 55 ◦ C for 30 s, then heating to
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97 ◦ C. The thermocycler conditions for gst were 95 ◦ C for 15 min, 40 cycles of denaturation
at 94 ◦ C for 10 s, annealing at 57 ◦ C for 20 s, and elongation at 72 ◦ C for 15 s [25,26]. The
melting curve analysis involved heating to 95 ◦ C for 1 min, annealing at 55 ◦ C for 30 s, then
heating to 97 ◦ C.
The standards were created by diluting 2 ng/µL of wsp plasmid and 2 ng/µL of gst
plasmid to obtain known copy numbers of the wsp and gst plasmid. The copy numbers of
the standards were plotted against the Ct values from the thermocycler results using MS
Excel, and a line of best fit was calculated. Prism 6.0 was used to analyze the data with a
Kruskal–Wallis non-parametric ANOVA test.
2.3. Primary Sequence-Based Comparisons of Aspartyl Proteases
Protein sequence data was downloaded from WormBase Parasite [27]: B. malayi
(PRJNA10729), B. pahangi (PRJEB497), O. ochengi (PRJEB1204), O. volvulus (PRJEB513),
T. muris (PRJEB126), and Caenorhabditis elegans (WBPS16). In addition, the human genome
(GRCh38.p13), downloaded from Ensembl [28], was used as an outgroup for comparisons.
Aspartyl proteases of Brugia spp., Onchocerca spp. and T. muris were annotated using
MEROPS [29]. All of the B. malayi aspartyl proteases identified by MEROPS were aligned
with HIV-1 protease (GenBank accession number: CAA09224) using T-Coffee [30] and
clustered with Clustal Omega [31]. Orthology was determined among the 6 nematode
species with human using Orthofinder with default settings [32]. Orthologous protein
families annotated as aspartyl proteases in Brugia spp., Onchocerca spp., and T. muris were
selected for multiple sequence alignment; construction of a phylogenetic tree using the
neighbor joining method was performed with MAFFT version 7 with default setting [33].
The alignment was visualized with Jalview [34].
Best bi-directional hits were identified based on protein alignment between the longest
isoforms per gene of B. malayi and those of B. pahangi using Diamond blastp (v2.0.6.144) [35].
This alignment was performed in “both directions” (once with B. malayi as the query and
once with B. pahangi as the query) and a local script was used to build a table of results,
with all cases in which proteins were top scoring hits next to each other in both directions
and flagged as being reciprocal hits. Gene symbols and descriptions were harvested from
the BioMart [36] instance hosted at WormBase Parasite [27] and were used to annotate
the results.
2.4. Histochemical Localization of the Aspartyl Proteases in Adult Female B. malayi
2.4.1. Immunohistology
A polyclonal rabbit antibody raised against a recombinant cathepsin D-like lysosomal
aspartic protease of the filarial parasite O. volvulus (GenBank accession number U81605)
was used as a primary antibody to label an orthologous protein in B. malayi [37]. Twelveweek-old adult B. malayi recovered from experimentally infected gerbils were fixed in 80%
ethanol and stained using the alkaline phosphatase/anti-alkaline phosphatase technique
as described previously [38].
2.4.2. Immunogold Transmission Electron Microscopy
For immunolabeling, we used high-pressure frozen B. malayi samples as described
previously [39]. The primary anti-polyclonal rabbit antibody was used at dilutions of
1:50 and 1:200 and as negative control, phosphate buffered saline was used instead of
the primary antibody. To visualize the primary rabbit antibody, an 18-nm colloidal goldconjugated goat anti-rabbit secondary antibody (Jackson ImmunoResearch, West Grove,
PA, USA) was used and sections were viewed on a JEM-1400 transmission microscope
(JEOL) at 80 kV with an AMT XR111 4 k digital camera.
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2.5. RNAseq of Adult Female B. pahangi In Vitro Treated with APIs and
Comparative Transcriptomics
2.5.1. Prepartion of In Vitro Treated Worms with APIs and Production of RNA-seq
For RNA-seq analysis, adult female B. pahangi (3 worms per replicate) were treated
with 1% DMSO (control) and 100 µM of lopinavir, nelfinavir, and ritonavir for 1 h of in vitro
treatment (all in triplicate) and stored at −80 ◦ C. Total RNA was isolated using Trizol
(Invitrogen, Waltham, MA, USA) after being homogenized with 1.5 mm zirconium beads
(Benchmark scientific, D1032-15) using BeadBug6 (Benchmark scientific, D1036, Sayreville,
NJ, USA). cDNA libraries were prepared from RNA samples with poly(A) enrichment
and processed cDNA was sequenced on the Illumina NovaSeq S4 platform (paired-end
150bp reads). Sequenced reads were mapped to the B. pahangi genome assembly (PRJEB497,
WBPS13 [27]) using STAR [40] and quantified per gene using featureCounts [41]. Relative
gene expression was calculated using “fragments per kilobase per million reads” (FPKM)
normalization per gene per sample. Fold change and differential expression significance
values (relative to DMSO controls) were calculated using DESeq2 [42] (version 1.34.0;
default settings, FDR ≤ 0.05). DESeq2 [42] was also used to perform PCA (default settings,
based on the top 500 most variable genes). The raw RNA-seq read files (fastq) are accessible
on the NCBI Sequence Read Archive (SRA [43], BioProject PRJNA840851). Complete
sample metadata, RNA-seq mapping statistics, and accession numbers per sample are
provided in Supplementary Table S2. Read counts and normalized expression values per
gene per sample are provided in Supplementary Table S3.
Gene expression profiles based on stage-specific RNA-seq datasets were generated
using the same processing approach applied to datasets from Choi et al. [44] for B. malayi,
and Foth et al. [45] for T. muris.
2.5.2. Functional Annotation of B. pahangi Genome for RNA-seq Analysis
Functional annotations for all B. pahangi genes were assigned using annotations from
InterProScan v5.42 [46] to identify gene ontology [47] classifications and InterPro functional
domains [48], and GhostKOALA v2.2 [49] to identify KEGG [50] annotations. MEROPS [29]
was used to identify 14 aspartic proteases in the B. pahangi genome. All functional annotation data are provided in Supplementary Table S3. Enriched KEGG pathways among
differentially expressed gene sets were identified using WebGestaltR [51] (minimum 2 genes
per pathway, p ≤ 0.05 threshold for significance).
3. Results
A previous study reported some HIV protease inhibitors that have macrofilaricidal
activity with stage and species specificity, identifying three aspartic protease inhibitors
(APIs) that effectively inhibited motility in adult female B. pahangi and adult O. ochengi male
and/or female worms [13]. To expand on these results, we first performed single-dose phenotypic screening on adult female B. malayi (human parasite) followed by determining IC50
values, evaluating whether the efficacy is via the Wolbachia endosymbiont or through direct
effects on the worm, performing immunolocalization of the potential aspartic protease
target, and interrogating the adult worm transcriptional response to treatment.
3.1. In Vitro Worm Motility Assays
Guided by the Tyagi et al. study [13], seven FDA-approved APIs were screened
against adult female B. malayi at either 30 µM or 50 µM in a motility assay (Figure 1A,
Supplementary Table S1). The worms treated with lopinavir, nelfinavir, and ritonavir
showed the highest motility inhibition at day one and consequently they were killed
by day 6 (Figure 1A). Worm motility was not inhibited by four (amprenavir, atazanavir,
darunavir, and pepstatin A) of the seven APIs, as previously shown in adult B. pahangi and
O. ochengi [13]. However, the three effective APIs had similar efficacy at 30 µM in both our
B. malayi assay and the previous B. pahangi assay after 6 days [13] (Figure 1B). To further
investigate the potency of the drugs, the IC50 values for lopinavir, nelfinavir, and ritonavir
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Figure 3. Sequence conservation and gene expression analysis of the B. malayi aspartic protease
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chords, the hypodermis, intrauterine stretched microfilariae, the uterine wall, and the intestinal wall.
((B–F) Immunogold TEM labeling of APR. (B) Section of the hypodermis showing parts of the cuticle,
muscles, mitochondria, and a large vacuole. (C) Magnification of (B) showing multiple clusters of
gold particles within the large vacuole. (D) Wolbachia in the lateral chord are not labeled by gold
particles, but small clusters of particles are found in nearby cytoplasm. (E) Mitochondria are also not
stained by the gold particles, but a large cluster of particles can be seen in moderately electron-dense
structures in the cytoplasm. (F) A large cluster of gold particles is associated with a vacuole in the
vicinity of vesicles released by Wolbachia endobacteria. Lc, lateral chord; dvc, dorsal/ventral chord;
u, uterus; I, intestine; m, muscles; hy, hypodermis; va, vacuole; mi, mitochondrion; cu, cuticle; w,
Wolbachia; ve, vesicles. Scale bar: (A) 25 µm, (B) 2 µm, (C–F) 500 nm.

3.5. Transcriptional Response of API-Treated Adult Female B. pahangi
The transcriptional response to API treatment was quantified using RNA-seq analysis
of adult female B. pahangi worms treated with 1% DMSO (control) and 100 µM of lopinavir,
nelfinavir, and ritonavir for 1 h (in vitro treatment, performed in triplicate). Sequencing
produced an average of 36 million reads, with an average of 92.6% of reads mapping to
the B. pahangi genome, following cleaning and processing (Supplementary Table S2). The
exposure time and concentration were selected based on the determined IC50 values in
order to optimally capture the immediate transcriptional response, including that of aspartic
protease-responsive genes, before downstream stress-response pathways were activated.
Principal components analysis (PCA) of RNA-seq datasets showed separate clustering
of the API-treated worms from the untreated group, suggesting the early transcriptomic
responses from the API-treated worms were distinct from those of the controls (Figure 5A).
Differential expression analysis identified significantly upregulated/downregulated genes
in lopinavir (upregulated: 204, downregulated: 105), nelfinavir (upregulated: 869, downregulated: 760), and ritonavir (upregulated:1226, downregulated: 1257) compared to DMSO
controls, respectively. Among them, more than 40% of differentially expressed genes were
shared with at least two comparison groups (upregulated: 49.2%, downregulated: 40.2%),
particularly between nelfinavir and ritonavir. This indicated that API treatments could elicit
common and unique transcriptional responses in adult female B. pahangi (Figure 5B). Four
of the 14 APs identified by MEROPS were differentially regulated by the APIs (Figure 5C).
Of these, two genes encoding cathepsin E (BPAG_1278201) and signal peptide peptidaselike protein (BPAG_106301) were significantly upregulated by ritonavir. A presenilin 1
gene (BPAG_1346801)—a critical regulator of ErbB/EGFR [53] signaling pathway—was
downregulated by both ritonavir and nelfinavir. Interestingly, a DNA damage-inducible 1
homolog (BPAG_1342901) whose activity can be directly inhibited with nelfinavir-treated
cancer cells [54,55], was significantly downregulated only in nelfinavir. Gene annotations,
read counts, normalized expression values, and differential expression statistics for all
genes in all samples are provided in Supplementary Table S3.
Next, we identified significantly enriched KEGG pathways among upregulated/
downregulated genes in the API treatments (Figure 6). Most enriched pathways were
observed in nelfinavir and ritonavir, due to the lack of differentially expressed genes in
lopinavir. We found that KEGG pathways involved in ubiquitin mediated proteolysis,
protein kinases and MAPK/AMPK/FoxO signaling pathways were significantly enriched
among upregulated genes in all API treatments (Figure 6A). Upregulation of genes related to the ubiquitin mediated proteolysis may be related to potential inhibition of the
filarial lysosomal AP (Figure 3C,E,H) by APIs, consequently affecting protein degradation
and increasing the burden of protein aggregates. The ubiquitin proteasome system and
autophagy-lysosomal pathway constitute a single network to regulate proteostasis [56]. In
addition, lopinavir, nelfinavir and/or ritonavir have been shown to trigger an accumulation
of unfolded proteins, subsequently inducing an unfolded protein response (UPR) and ER
stress, which can result in cell cycle arrest and/or apoptosis in mammalian cells [57–63].
Signaling pathways such as MAPK are evolutionarily conserved mechanisms for regulating cellular proliferation, differentiation, and survival, and can be activated via various
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To identify the potential targets of the APIs in filarial worms, we first conducted
protein sequence-based clustering of the APs in B. malayi with HIV-1 aspartyl protease,
followed by transcriptomic profiling across B. malayi life stages. We identified that some
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APs showed stage- and/or sex-specific expression, but two of the three APs (all belong to
the A01A class of aspartic proteases) that were the most homologous to HIV1-PR (Bm8660:
lysosomal aspartic protease or cathepsin D and Bm3492) were particularly over-expressed
in L4 and adult stages, which potentially implicated their important roles in these clinically
relevant stages (Figure 3A). This observation was also validated by immunolocalization
of the lysosomal AP in adult B. malayi. This protein was specifically localized in large
vacuoles of the hypodermis and the lateral and dorsal/ventral chords of adult female
worms (Figure 4A–F). The density of typical, smaller lysosomes increases with the age
of the worms and no lysosomes were found in the examined sections of the very young
adult stage females used. Additionally, the lysosomal AP was identified in an orthologous
protein family conserved in different species, including the filarial worms, whipworm (T.
muris), C. elegans, and human (Figure 3B). Intriguingly, the orthologous lysosomal AP genes
were identified as single-copy orthologs, while the orthologous genes to Bm3492 seemed to
undergo several duplication events, especially in C. elegans and human (Supplementary
Figure S1). These results imply strict conservation of the lysosomal APs, given the last
common ancestor and the indispensable functional role of the APs in protein homeostasis
across different species.
The primary goal of the RNA-seq analysis was to capture the early transcriptional
responses of adult female B. pahangi after the in vitro API treatments, in the hope that we
could identify differential gene responses to the aspartic proteases and identify molecular
pathways affected by treatment. The differential expression analysis showed that four of
the 14 AP genes in B. pahangi were differentially expressed in nelfinavir and/or ritonavir,
but not in lopinavir (Figure 5C). Lopinavir showed the least transcriptional responses,
compared with nelfinavir and ritonavir, possibly because strong transcriptional changes
may occur more gradually with this drug (Figure 5B). One of three biological replicates
closely clustered with the untreated group (thus, considered as an outlier and removed
from downstream analysis) and the other two replicates had a lower correlation coefficient
compared with the replicates of the other two APIs, resulting in the under-detection of
DEGs in lopinavir-treated worms. It is possible that in vitro treatment of lopinavir at
100 µM for 1 h may not be sufficient to trigger significant transcriptional changes in adult
female B. pahangi; the motility of the worms after the treatments was not critically affected
(data not shown).
Of the four AP genes differentially expressed in the API treatment, BPAG_1278201
(predicted as cathepsin E; CTSE) was found to be significantly upregulated by ritonavir
(Figure 5C), which has been shown to have a high affinity for CTSE binding in previous research, which utilized it as a marker for CTSE detection [68,69]. BPAG_201201 (presenilin 1,
PS1), predicted to be involved in regulating ErbB signaling receptor turnover, was downregulated by both ritonavir and nelfinavir (Figure 5C) [53]. Furthermore, our pathway
enrichment analysis indicated upregulation of genes in the ErbB/EGFR pathways in both
treatments with simultaneous downregulation of this PS1 gene (Figures 5C and 6A). Finally,
BPAG_1342901 (a DNA damage-inducible 1 homolog, DDI-1 or DDI-2) was significantly
downregulated only in nelfinavir (Figure 5C). Previous studies demonstrated that DDI-2
protease resembled the 3D structure of the HIV protease, and nelfinavir could interfere with
the proteasomal activity of DDI-2 [54,55,70]. Along with lysosomal protein degradation, the
ubiquitin-proteasome system is a part of major proteolytic systems that play essential roles
in degrading unnecessary proteins polyubiquitinated by ubiquitin [56]. In the immunohistological analysis, the highly expressed B. malayi lysosomal aspartic protease Bm8660
(which is the ortholog of the known API target in HIV) was identified in large vacuoles and
other electron-dense structures in the cytoplasm, suggesting that is it potentially highly
abundant in lysosomes, as expected based on results from other species. The RNA-seq
results also show enrichment for common highly-expressed lysosomal-associated pathways
among differentially expressed genes, further supporting this identification. However, since
young adult worms were used, the exact positions of lysosomes could not be determined.
The dysregulation of the protein homeostasis can result in activation of unfolded protein
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response (UPR) and ER stress in the cells [59]. Interestingly, we observed upregulation
of genes involved in the ubiquitin-mediated proteolysis pathway and the various kinase
signaling pathways (Figure 6), which may be cellular survival cues to resolve UPR and ER
stress caused by the burden of accumulation of unfolded proteins.
In summary, this study demonstrated that the three APIs (lopinavir, nelfinavir, and
ritonavir) originally designed to treat HIV infection could be repurposed to interrupt the
transmission of filarial and/or gastro-intestinal infections by inhibiting the motility of
adult worms. We also suggested a lysosomal aspartic protease as a potential target of the
active API(s) based on the observations from protein sequence conservation, characteristic
expression signatures at L4 and adult stages, immunolocalization, and drug-responsive
transcriptional profiles from adult female worms. However, the specific molecular target
of HIV protease inhibitors is still unclear; suggested potential targets include not only
HIV-1 aspartic protease, but also heat-shock protein 90 (HSP90), cytochrome P450 3A4
(CYP3A4), and/or P-glycoprotein [71]. Therefore, in addition to the lysosomal aspartic
proteases suggested in this study, the evaluation of other potential molecular targets
should be considered in future experiments. Future studies are needed to confirm the
molecular targets of these APIs and to help in understand the essentiality of these targets
for parasitic nematode survival. While, historically, there has been a weak relationship
between hits discovered in vitro and their efficacy in vivo [72], selective drug optimization
could be followed by in vivo activity confirmation using animal models for filarial infection
(jirds) and gastro-intestinal whipworm (mice) using human-equivalent dosages that are
predicted based on animal PK data and the human safety and clinical information of the
FDA-approved APIs.
5. Conclusions
Overall, this project has contributed to the discovery of potential new scaffolds that
can be further explored to identify lead compounds that need to be further optimized.
B. malayi, one of the parasitic nematode species that causes lymphatic filariasis and the
gastro-intestinal whipworm, T. muris, have several aspartyl proteases that are conserved
with the HIV-1 aspartyl protease and that are over-expressed in the adult female life stage.
Thus, these aspartyl proteases may be the targets of the HIV antiretroviral drugs. This
study revealed that the APIs lopinavir, nelfinavir, and ritonavir have a direct effect in
killing the adult stages of two phylogenetically very different parasitic nematodes. This
study also provided new insights on the filarial response to treatment at the transcriptional
level. Future in vitro studies are necessary to validate the target of these APIs, to optimize
the API structures to increase potency, and to follow up with in vivo studies for safety
and pharmacokinetics, eventually leading to in vivo studies in animal model for filarial
and whipworm infection. Furthermore, additional studies are necessary to determine
the therapeutic indices and physiological pharmacokinetics for these drugs as anti-filarial
drugs. Overall, the results of this study suggest APIs may serve as new leads for drug
discovery of filarial, gastro-intestinal, and potentially other diseases.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3
390/pathogens11060707/s1, Supplementary Figure S1: Sequence based-clustering of proteins from 14
aspartic protease orthologous protein families (OPFs) identified in B. pahangi; Supplementary Table S1:
Motility inhibition (%) of adult Brugia species treated in vitro with aspartyl protease inhibitors.
Supplementary Table S2: RNA-seq sample metadata including read mapping statistics and raw data
accession identifiers; Supplementary Table S3: B. pahangi gene annotations, BLAST matches to B.
malayi, raw read counts, and normalized gene expression levels (RNA-seq) for all genes.
Author Contributions: Conceptualization, M.M., J.W.J., S.L. and J.A.S.; methodology and experiments, L.B., H.J., C.A.B. and P.U.F.; formal analysis, L.B. and H.J.; resources, J.A.S. and M.M.; data
curation, L.B. and H.J.; writing—original draft preparation, L.B., H.J., P.U.F., S.L., J.W.J., J.A.S. and
M.M.; writing—review and editing, J.A.S. and M.M.; visualization, L.B., H.J., B.A.R. and P.U.F.;
supervision, M.M. and J.A.S.; funding acquisition, M.M. All authors have read and agreed to the
published version of the manuscript.

Pathogens 2022, 11, 707

14 of 17

Funding: This research was funded in part by the National Institute of Allergy and Infectious
Diseases, grant number 1R01AI159450.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: All unprocessed RNA-seq data are available on the NCBI Short Reads
Archive (SRA, BioProject PRJNA840851). Accessions per sample are available in Supplementary
Table S2 and complete-processed RNA-seq read counts, gene expression values, and annotations are
available in Supplementary Table S3.
Acknowledgments: We thank Wandy Beatty from the Molecular Microbiology Imaging Core Facility
of Washington University for the TEM immunolabeling of B. malayi sections, and Kerstin Fischer for
her expert technical support with the immunolocalization. The immunolocalization was supported
by the Foundation of the Barnes Jewish Hospital. We thank John Martin for analytical processing
and submission of the RNA-seq data, and Joseph F. Urban from the USDA for providing adult
T. muris. The following reagents were provided by the NIH/NIAID Filariasis Research Reagent
Resource Center for distribution through BEI Resources, NIAID, NIH: Adult Female Brugia malayi
(live), NR-48892 and Adult Female Brugia pahangi (live), NR-48903.
Conflicts of Interest: The authors declare no conflict of interest.

References
1.
2.
3.
4.
5.

6.
7.
8.
9.
10.
11.
12.
13.

14.
15.

16.
17.
18.

Mitra, A.K.; Mawson, A.R. Neglected Tropical Diseases: Epidemiology and Global Burden. Trop. Med. Infect. Dis. 2017, 2, 36.
[CrossRef] [PubMed]
WHO. Lymphatic Filariasis. In World Health Organization Fact Sheets; WHO: Geneva, Switzerland. Available online: https:
//www.who.int/news-room/fact-sheets/detail/lymphatic-filariasis (accessed on 15 June 2022).
Taylor, M.J.; Hoerauf, A.; Bockarie, M. Lymphatic filariasis and onchocerciasis. Lancet 2010, 376, 1175–1185. [CrossRef]
King, C.L.; Suamani, J.; Sanuku, N.; Cheng, Y.C.; Satofan, S.; Mancuso, B.; Goss, C.W.; Robinson, L.J.; Siba, P.M.; Weil, G.J.; et al. A
Trial of a Triple-Drug Treatment for Lymphatic Filariasis. N. Engl. J. Med. 2018, 379, 1801–1810. [CrossRef] [PubMed]
Wan Sulaiman, W.A.; Kamtchum-Tatuene, J.; Mohamed, M.H.; Ramachandran, V.; Ching, S.M.; Sazlly Lim, S.M.; Hashim, H.Z.;
Inche Mat, L.N.; Hoo, F.K.; Basri, H. Anti-Wolbachia therapy for onchocerciasis & lymphatic filariasis: Current perspectives.
Indian J. Med. Res. 2019, 149, 706–714. [CrossRef] [PubMed]
Ottesen, E.A.; Hooper, P.J.; Bradley, M.; Biswas, G. The global programme to eliminate lymphatic filariasis: Health impact after 8
years. PLoS Negl. Trop. Dis. 2008, 2, e317. [CrossRef] [PubMed]
Molyneux, D.H.; Taylor, M.J. Current status and future prospects of the Global Lymphatic Filariasis Programme. Curr. Opin.
Infect. Dis. 2001, 14, 155–159. [CrossRef]
Local Burden of Disease Neglected Tropical Diseases, C. The global distribution of lymphatic filariasis, 2000–2018: A geospatial
analysis. Lancet Glob. Health 2020, 8, e1186–e1194. [CrossRef]
Mathew, C.G.; Bettis, A.A.; Chu, B.K.; English, M.; Ottesen, E.A.; Bradley, M.H.; Turner, H.C. The Health and Economic Burdens
of Lymphatic Filariasis Prior to Mass Drug Administration Programs. Clin. Infect. Dis. 2020, 70, 2561–2567. [CrossRef]
Newman, T.E.; Juergens, A.L. Filariasis. In StatPearls; StatPearls: Treasure Island, FL, USA, 2022.
Grote, A.; Voronin, D.; Ding, T.; Twaddle, A.; Unnasch, T.R.; Lustigman, S.; Ghedin, E. Defining Brugia malayi and Wolbachia
symbiosis by stage-specific dual RNA-seq. PLoS Negl. Trop. Dis. 2017, 11, e0005357. [CrossRef]
Taylor, M.J.; Bordenstein, S.R.; Slatko, B. Microbe Profile: Wolbachia: A sex selector, a viral protector and a target to treat filarial
nematodes. Microbiology 2018, 164, 1345–1347. [CrossRef]
Tyagi, R.; Bulman, C.A.; Cho-Ngwa, F.; Fischer, C.; Marcellino, C.; Arkin, M.R.; McKerrow, J.H.; McNamara, C.W.; Mahoney, M.;
Tricoche, N.; et al. An Integrated Approach to Identify New Anti-Filarial Leads to Treat River Blindness, a Neglected Tropical
Disease. Pathogens 2021, 10, 71. [CrossRef] [PubMed]
Alavi, S.E.; Ebrahimi Shahmabadi, H. Anthelmintics for drug repurposing: Opportunities and challenges. Saudi Pharm. J. 2021,
29, 434–445. [CrossRef] [PubMed]
Janes, J.; Young, M.E.; Chen, E.; Rogers, N.H.; Burgstaller-Muehlbacher, S.; Hughes, L.D.; Love, M.S.; Hull, M.V.; Kuhen, K.L.;
Woods, A.K.; et al. The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of
cryptosporidiosis. Proc. Natl. Acad. Sci. USA 2018, 115, 10750–10755. [CrossRef] [PubMed]
Panic, G.; Duthaler, U.; Speich, B.; Keiser, J. Repurposing drugs for the treatment and control of helminth infections. Int. J.
Parasitol. Drugs Drug Resist. 2014, 4, 185–200. [CrossRef] [PubMed]
Lv, Z.; Chu, Y.; Wang, Y. HIV protease inhibitors: A review of molecular selectivity and toxicity. HIV/AIDS-Res. Palliat. Care 2015,
7, 95–104. [CrossRef]
Lopez-Otin, C.; Bond, J.S. Proteases: Multifunctional enzymes in life and disease. J. Biol. Chem. 2008, 283, 30433–30437. [CrossRef]
[PubMed]

Pathogens 2022, 11, 707

19.
20.
21.
22.

23.
24.

25.
26.

27.
28.
29.

30.
31.

32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.

15 of 17

Santos, R.; Ursu, O.; Gaulton, A.; Bento, A.P.; Donadi, R.S.; Bologa, C.G.; Karlsson, A.; Al-Lazikani, B.; Hersey, A.; Oprea, T.I.; et al.
A comprehensive map of molecular drug targets. Nat. Rev. Drug Discov. 2017, 16, 19–34. [CrossRef]
International Helminth Genomes, C. Comparative genomics of the major parasitic worms. Nat. Genet. 2019, 51, 163–174.
[CrossRef]
Donohue, R.E.; Cross, Z.K.; Michael, E. The extent, nature, and pathogenic consequences of helminth polyparasitism in humans:
A meta-analysis. PLoS Negl. Trop. Dis. 2019, 13, e0007455. [CrossRef]
Bulman, C.A.; Bidlow, C.M.; Lustigman, S.; Cho-Ngwa, F.; Williams, D.; Rascon, A.A., Jr.; Tricoche, N.; Samje, M.; Bell, A.; Suzuki,
B.; et al. Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis. PLoS Negl. Trop. Dis.
2015, 9, e0003534. [CrossRef]
Marcellino, C.; Gut, J.; Lim, K.C.; Singh, R.; McKerrow, J.; Sakanari, J. WormAssay: A novel computer application for whole-plate
motion-based screening of macroscopic parasites. PLoS Negl. Trop. Dis. 2012, 6, e1494. [CrossRef] [PubMed]
Jasmer, D.P.; Rosa, B.A.; Tyagi, R.; Bulman, C.A.; Beerntsen, B.; Urban, J.F., Jr.; Sakanari, J.; Mitreva, M. De novo identification of
toxicants that cause irreparable damage to parasitic nematode intestinal cells. PLoS Negl. Trop. Dis. 2020, 14, e0007942. [CrossRef]
[PubMed]
McGarry, H.F.; Egerton, G.L.; Taylor, M.J. Population dynamics of Wolbachia bacterial endosymbionts in Brugia malayi. Mol.
Biochem. Parasitol. 2004, 135, 57–67. [CrossRef] [PubMed]
Gunderson, E.L.; Vogel, I.; Chappell, L.; Bulman, C.A.; Lim, K.C.; Luo, M.; Whitman, J.D.; Franklin, C.; Choi, Y.J.; Lefoulon,
E.; et al. The endosymbiont Wolbachia rebounds following antibiotic treatment. PLoS Pathog. 2020, 16, e1008623. [CrossRef]
[PubMed]
Howe, K.L.; Bolt, B.J.; Shafie, M.; Kersey, P.; Berriman, M. WormBase ParaSite—A comprehensive resource for helminth genomics.
Mol. Biochem. Parasitol. 2017, 215, 2–10. [CrossRef]
Howe, K.L.; Achuthan, P.; Allen, J.; Allen, J.; Alvarez-Jarreta, J.; Amode, M.R.; Armean, I.M.; Azov, A.G.; Bennett, R.; Bhai, J.; et al.
Ensembl 2021. Nucleic Acids Res. 2021, 49, D884–D891. [CrossRef]
Rawlings, N.D.; Barrett, A.J.; Thomas, P.D.; Huang, X.; Bateman, A.; Finn, R.D. The MEROPS database of proteolytic enzymes,
their substrates and inhibitors in 2017 and a comparison with peptidases in the PANTHER database. Nucleic Acids Res. 2018, 46,
D624–D632. [CrossRef]
Notredame, C.; Higgins, D.G.; Heringa, J. T-Coffee: A novel method for fast and accurate multiple sequence alignment. J. Mol.
Biol. 2000, 302, 205–217. [CrossRef]
Sievers, F.; Wilm, A.; Dineen, D.; Gibson, T.J.; Karplus, K.; Li, W.; Lopez, R.; McWilliam, H.; Remmert, M.; Soding, J.; et al. Fast,
scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 2011, 7, 539.
[CrossRef]
Emms, D.M.; Kelly, S. OrthoFinder: Phylogenetic orthology inference for comparative genomics. Genome Biol. 2019, 20, 238.
[CrossRef]
Katoh, K.; Rozewicki, J.; Yamada, K.D. MAFFT online service: Multiple sequence alignment, interactive sequence choice and
visualization. Brief. Bioinform. 2019, 20, 1160–1166. [CrossRef] [PubMed]
Waterhouse, A.M.; Procter, J.B.; Martin, D.M.; Clamp, M.; Barton, G.J. Jalview Version 2–a multiple sequence alignment editor
and analysis workbench. Bioinformatics 2009, 25, 1189–1191. [CrossRef] [PubMed]
Buchfink, B.; Reuter, K.; Drost, H.G. Sensitive protein alignments at tree-of-life scale using DIAMOND. Nat. Methods 2021, 18,
366–368. [CrossRef] [PubMed]
Kinsella, R.J.; Kahari, A.; Haider, S.; Zamora, J.; Proctor, G.; Spudich, G.; Almeida-King, J.; Staines, D.; Derwent, P.; Kerhornou,
A.; et al. Ensembl BioMarts: A hub for data retrieval across taxonomic space. Database 2011, 2011, bar030. [CrossRef] [PubMed]
Jolodar, A.; Fischer, P.; Buttner, D.W.; Miller, D.J.; Schmetz, C.; Brattig, N.W. Onchocerca volvulus: Expression and immunolocalization of a nematode cathepsin D-like lysosomal aspartic protease. Exp. Parasitol. 2004, 107, 145–156. [CrossRef]
Fischer, K.; Beatty, W.L.; Jiang, D.; Weil, G.J.; Fischer, P.U. Tissue and stage-specific distribution of Wolbachia in Brugia malayi.
PLoS Negl. Trop. Dis. 2011, 5, e1174. [CrossRef]
Fischer, K.; Beatty, W.L.; Weil, G.J.; Fischer, P.U. High pressure freezing/freeze substitution fixation improves the ultrastructural
assessment of Wolbachia endosymbiont-filarial nematode host interaction. PLoS ONE 2014, 9, e86383. [CrossRef]
Dobin, A.; Davis, C.A.; Schlesinger, F.; Drenkow, J.; Zaleski, C.; Jha, S.; Batut, P.; Chaisson, M.; Gingeras, T.R. STAR: Ultrafast
universal RNA-seq aligner. Bioinformatics 2013, 29, 15–21. [CrossRef]
Liao, Y.; Smyth, G.K.; Shi, W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic
features. Bioinformatics 2014, 30, 923–930. [CrossRef]
Anders, S.; Huber, W. Differential expression analysis for sequence count data. Genome Biol. 2010, 11, R106. [CrossRef]
Leinonen, R.; Sugawara, H.; Shumway, M. The Sequence Read Archive. Nucleic Acids Res. 2011, 39, D19–D21. [CrossRef]
[PubMed]
Choi, Y.J.; Ghedin, E.; Berriman, M.; McQuillan, J.; Holroyd, N.; Mayhew, G.F.; Christensen, B.M.; Michalski, M.L. A deep
sequencing approach to comparatively analyze the transcriptome of lifecycle stages of the filarial worm, Brugia malayi. PLoS
Negl. Trop. Dis. 2011, 5, e1409. [CrossRef] [PubMed]

Pathogens 2022, 11, 707

45.

46.
47.
48.
49.
50.
51.
52.

53.
54.
55.
56.

57.

58.

59.
60.

61.
62.

63.

64.
65.

66.
67.

68.

16 of 17

Foth, B.J.; Tsai, I.J.; Reid, A.J.; Bancroft, A.J.; Nichol, S.; Tracey, A.; Holroyd, N.; Cotton, J.A.; Stanley, E.J.; Zarowiecki, M.; et al.
Whipworm genome and dual-species transcriptome analyses provide molecular insights into an intimate host-parasite interaction.
Nat. Genet. 2014, 46, 693–700. [CrossRef] [PubMed]
Jones, P.; Binns, D.; Chang, H.Y.; Fraser, M.; Li, W.; McAnulla, C.; McWilliam, H.; Maslen, J.; Mitchell, A.; Nuka, G.; et al.
InterProScan 5: Genome-scale protein function classification. Bioinformatics 2014, 30, 1236–1240. [CrossRef] [PubMed]
Gene Ontology, C. The Gene Ontology resource: Enriching a GOld mine. Nucleic Acids Res. 2021, 49, D325–D334. [CrossRef]
Blum, M.; Chang, H.Y.; Chuguransky, S.; Grego, T.; Kandasaamy, S.; Mitchell, A.; Nuka, G.; Paysan-Lafosse, T.; Qureshi, M.; Raj,
S.; et al. The InterPro protein families and domains database: 20 years on. Nucleic Acids Res. 2021, 49, D344–D354. [CrossRef]
Kanehisa, M.; Sato, Y.; Morishima, K. BlastKOALA and GhostKOALA: KEGG Tools for Functional Characterization of Genome
and Metagenome Sequences. J. Mol. Biol. 2016, 428, 726–731. [CrossRef]
Kanehisa, M.; Furumichi, M.; Sato, Y.; Ishiguro-Watanabe, M.; Tanabe, M. KEGG: Integrating viruses and cellular organisms.
Nucleic Acids Res. 2021, 49, D545–D551. [CrossRef]
Liao, Y.; Wang, J.; Jaehnig, E.J.; Shi, Z.; Zhang, B. WebGestalt 2019: Gene set analysis toolkit with revamped UIs and APIs. Nucleic
Acids Res. 2019, 47, W199–W205. [CrossRef]
Hoerauf, A.; Nissen-Pahle, K.; Schmetz, C.; Henkle-Duhrsen, K.; Blaxter, M.L.; Buttner, D.W.; Gallin, M.Y.; Al-Qaoud, K.M.;
Lucius, R.; Fleischer, B. Tetracycline therapy targets intracellular bacteria in the filarial nematode Litomosoides sigmodontis and
results in filarial infertility. J. Clin. Invest. 1999, 103, 11–18. [CrossRef]
Repetto, E.; Yoon, I.S.; Zheng, H.; Kang, D.E. Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in
the endosomal-lysosomal pathway. J. Biol. Chem. 2007, 282, 31504–31516. [CrossRef] [PubMed]
Gu, Y.; Wang, X.; Wang, Y.; Wang, Y.; Li, J.; Yu, F.X. Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome
inhibitors. Cell Signal. 2020, 75, 109775. [CrossRef] [PubMed]
Chen, T.; Ho, M.; Briere, J.; Moscvin, M.; Czarnecki, P.G.; Anderson, K.C.; Blackwell, T.K.; Bianchi, G. Multiple myeloma cells
depend on the DDI2/NRF1-mediated proteasome stress response for survival. Blood Adv. 2022, 6, 429–440. [CrossRef] [PubMed]
Bustamante, H.A.; Gonzalez, A.E.; Cerda-Troncoso, C.; Shaughnessy, R.; Otth, C.; Soza, A.; Burgos, P.V. Interplay Between the
Autophagy-Lysosomal Pathway and the Ubiquitin-Proteasome System: A Target for Therapeutic Development in Alzheimer’s
Disease. Front. Cell. Neurosci. 2018, 12, 126. [CrossRef]
Bruning, A.; Burger, P.; Vogel, M.; Rahmeh, M.; Gingelmaiers, A.; Friese, K.; Lenhard, M.; Burges, A. Nelfinavir induces the
unfolded protein response in ovarian cancer cells, resulting in ER vacuolization, cell cycle retardation and apoptosis. Cancer Biol.
Ther. 2009, 8, 226–232. [CrossRef]
Srirangam, A.; Mitra, R.; Wang, M.; Gorski, J.C.; Badve, S.; Baldridge, L.; Hamilton, J.; Kishimoto, H.; Hawes, J.; Li, L.; et al. Effects
of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin. Cancer Res. 2006, 12, 1883–1896.
[CrossRef]
Zhou, H.; Pandak, W.M., Jr.; Lyall, V.; Natarajan, R.; Hylemon, P.B. HIV protease inhibitors activate the unfolded protein response
in macrophages: Implication for atherosclerosis and cardiovascular disease. Mol. Pharmacol. 2005, 68, 690–700. [CrossRef]
Bode, H.; Schmidt, W.; Schulzke, J.D.; Fromm, M.; Zippel, T.; Wahnschaffe, U.; Bendfeldt, K.; Riecken, E.O.; Ullrich, R. The HIV
protease inhibitors saquinavir, ritonavir, and nelfinavir but not indinavir impair the epithelial barrier in the human intestinal cell
line HT-29/B6. AIDS 1999, 13, 2595–2597. [CrossRef]
Bode, H.; Schmidt, W.; Schulzke, J.D.; Fromm, M.; Riecken, E.O.; Ullrich, R. Effects of HIV protease inhibitors on barrier function
in the human intestinal cell line HT-29/B6. Ann. N. Y. Acad. Sci. 2000, 915, 117–122. [CrossRef]
Bode, H.; Lenzner, L.; Kraemer, O.H.; Kroesen, A.J.; Bendfeldt, K.; Schulzke, J.D.; Fromm, M.; Stoltenburg-Didinger, G.; Zeitz, M.;
Ullrich, R. The HIV protease inhibitors saquinavir, ritonavir, and nelfinavir induce apoptosis and decrease barrier function in
human intestinal epithelial cells. Antivir. Ther. 2005, 10, 645–655. [CrossRef]
Zhou, H.; Gurley, E.C.; Jarujaron, S.; Ding, H.; Fang, Y.; Xu, Z.; Pandak, W.M., Jr.; Hylemon, P.B. HIV protease inhibitors activate
the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol.
2006, 291, G1071–G1080. [CrossRef] [PubMed]
Plotnikov, A.; Zehorai, E.; Procaccia, S.; Seger, R. The MAPK cascades: Signaling components, nuclear roles and mechanisms of
nuclear translocation. Biochim. Biophys. Acta 2011, 1813, 1619–1633. [CrossRef] [PubMed]
Lustigman, S.; Melnikow, E.; Anand, S.B.; Contreras, A.; Nandi, V.; Liu, J.; Bell, A.; Unnasch, T.R.; Rogers, M.B.; Ghedin, E.
Potential involvement of Brugia malayi cysteine proteases in the maintenance of the endosymbiotic relationship with Wolbachia.
Int. J. Parasitol. Drugs Drug Resist. 2014, 4, 267–277. [CrossRef] [PubMed]
CDC. DPDx—Laboratory Identification of Parasites of Public Health Concern: Lymphatic Filariasis. Available online: https:
//www.cdc.gov/dpdx/lymphaticfilariasis/index.html (accessed on 8 November 2020).
Chirgwin, S.R.; Coleman, S.U.; Porthouse, K.H.; Nowling, J.M.; Punkosdy, G.A.; Klei, T.R. Removal of Wolbachia from Brugia
pahangi is closely linked to worm death and fecundity but does not result in altered lymphatic lesion formation in Mongolian
gerbils (Meriones unguiculatus). Infect. Immun. 2003, 71, 6986–6994. [CrossRef]
Kempf, D.J.; Marsh, K.C.; Denissen, J.F.; McDonald, E.; Vasavanonda, S.; Flentge, C.A.; Green, B.E.; Fino, L.; Park, C.H.; Kong,
X.P.; et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.
Proc. Natl. Acad. Sci. USA 1995, 92, 2484–2488. [CrossRef]

Pathogens 2022, 11, 707

69.
70.
71.
72.

17 of 17

Keliher, E.J.; Reiner, T.; Earley, S.; Klubnick, J.; Tassa, C.; Lee, A.J.; Ramaswamy, S.; Bardeesy, N.; Hanahan, D.; Depinho, R.A.; et al.
Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection. Neoplasia 2013, 15, 684–693. [CrossRef]
Fassmannova, D.; Sedlak, F.; Sedlacek, J.; Spicka, I.; Grantz Saskova, K. Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome
Recovery Pathway in Multiple Myeloma. Cancers 2020, 12, 1065. [CrossRef]
Sato, A. The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies.
Onco Targets Ther. 2015, 8, 761–768. [CrossRef]
Rao, R.U.; Huang, Y.; Fischer, K.; Fischer, P.U.; Weil, G.J. Brugia malayi: Effects of nitazoxanide and tizoxanide on adult worms
and microfilariae of filarial nematodes. Exp. Parasitol. 2009, 121, 38–45. [CrossRef]

